AB Science S.A

AB Science announced the success of capital increases totaling 14.2 million euros in a private placement subscribed by a limited number of investors. A long-term historical investor contributed 12 million euros, and CEO Stéphane Ledermann also participated, stating the funding secures working capital for the coming months and supports the company's transformation. The placement involved issuing 23,278,692 new ordinary shares with attached warrants at 0.61 euros per unit, representing a 24.87% discount to the three-day volume-weighted average price. Proceeds will fund R&D priorities including AB8939 for acute myeloid leukemia, masitinib for amyotrophic lateral sclerosis, and near-term value-creation projects to be announced in September. Following the transaction, AB Science's cash position is approximately 23 million euros, covering financing needs beyond the next 12 months.

The Alzheimer's disease market across the seven major markets was valued at approximately USD 4 billion in 2025 and is projected to expand at a CAGR of 22.7% through 2036, according to DelveInsight. The growth is driven by increasing disease prevalence, broader adoption of disease-modifying therapies, advancements in biomarker-based diagnosis, and a robust late-stage pipeline. Key emerging therapies include Masupirdine from Suven Life Sciences, Roche's Trontinemab, Annovis Bio's Buntanetap, AB Science's Masitinib, Eli Lilly's Remternetug, Axsome Therapeutics' AUVELITY, Biovie's Bezisterim, ALZHEON's Valiltramiprosate, TauRx Therapeutics' Hydromethylthionine mesylate, Bristol Myers Squibb's COBENFY, AriBio's AR1001, Acadia Pharmaceuticals' Remlifanserin, and Cerecin's Tricaprilin. The report highlights six late-stage candidates poised to enter the market, including Masupirdine, Trontinemab, AXS-05, COBENFY, Remternetug, and Buntanetap, each with distinct mechanisms of action and anticipated clinical milestones.

AB Science is discontinuing three non-priority clinical studies to concentrate resources on its AB8939 program for acute myeloid leukemia and its masitinib program for amyotrophic lateral sclerosis. The discontinued studies are a Phase 2 trial of masitinib in mast cell activation syndrome, a Phase 3 trial of masitinib in mastocytosis, and a Phase 3 trial of masitinib in progressive forms of multiple sclerosis. The company stated that the discontinuation is not related to safety concerns and that it intends to complete the studies in accordance with regulations. For the AB8939 program, AB Science has completed Phase 1 Step 3 evaluating the combination of AB8939 and venetoclax and plans to seek authorization to initiate Phase 4, which will test a triple combination of AB8939, venetoclax, and azacitidine. The Phase 3 masitinib trial in amyotrophic lateral sclerosis, approved in 2025 but not yet started, will undergo a protocol update and require health authority authorization to resume.

AB Science has successfully completed a private placement raising EUR 2.3 million through the issuance of 3,475,758 new ordinary shares with warrants attached. The proceeds will primarily fund the AB8939 program in acute myeloid leukemia and masitinib in amyotrophic lateral sclerosis, extending the company's cash runway beyond the next 12 months. The units were priced at EUR 0.66 each, a 24.23% discount to the three-day volume-weighted average price, and each warrant entitles the holder to subscribe for one additional share at EUR 0.93 within 60 months. Following the placement, the company's share capital will consist of 73,251,991 ordinary shares, with the new shares expected to begin trading on Euronext Paris on July 6, 2026.

AB Science a annoncé l'achèvement de l'étape 3 de son essai de phase 1 évaluant la combinaison d'AB8939 et du vénétoclax chez des patients atteints de leucémie myéloïde aiguë réfractaire ou en rechute. La combinaison a généré un taux de réponse globale de 67% et un taux de contrôle de la maladie de 100% chez six patients lourdement prétraités présentant des profils génétiques défavorables, sans toxicité limitant la dose observée. Les patients traités avaient reçu de deux à quatre lignes de traitement antérieures et présentaient des anomalies telles que des mutations TP53, des caryotypes complexes ou des réarrangements MECOM. La dose recommandée pour la phase 2 a été sélectionnée, et la prochaine étape évaluera la triple combinaison AB8939, vénétoclax et azacitidine. AB8939 est un candidat médicament qui cible les cellules cancéreuses en déstabilisant les microtubules et les cellules souches cancéreuses en inhibant les enzymes ALDH.